V1
V16.F Virbac SA
- Market cap
- EUR 2.94B
- P/E
- 18.9x
- P/B
- 2.42x
- ROE
- 13.4%
- Dividend yield
- 0.41%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is V16.F undervalued?
Graham numberV16.F trades 42.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Virbac SA fundamental analysis
No fundamental analysis for Virbac SA yet.
Virbac SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Virbac SA
Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, the United States, Brazil, and the Pacific. The company offers Vikaly, a cat food designed for the management of feline chronic kidney disease; Prevexto that contains imidacloprid and flumethrin, providing long-lasting parasite protection collar for dogs and cats at risk of fleas, ticks, lice, and…
Full company profileVirbac SA financial statements
Virbac SA annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 872M | 862M | 869M | 938M | 934M | 1.06B | 1.22B | 1.25B | 1.40B | 1.46B |
| Gross Profit | 568M | 554M | 571M | 620M | 618M | 713M | 795M | 810M | 938M | 975M |
| Operating Income | 68.2M | 65.5M | 75.9M | 106M | 125M | 167M | 182M | 186M | 228M | 230M |
| EBITDA | - | 104M | 115M | 155M | 244M | 208M | 229M | 231M | 276M | 287M |
| Net Income | 34.6M | -2.58M | 20.1M | 51.6M | 137M | 113M | 122M | 121M | 145M | 151M |
| EPS | - | -0.31 | 2.39 | 6.11 | 16 | 13 | 14 | 14 | 17 | 18 |
| Balance Sheet | ||||||||||
| Total Assets | 1.42B | 1.28B | 1.27B | 1.32B | 1.11B | 1.20B | 1.33B | 1.46B | 1.85B | 1.91B |
| Total Liabilities | 896M | 798M | 777M | 771M | 454M | 476M | 495M | 546M | 805M | 789M |
| Shareholders' Equity | 474M | 436M | 460M | 518M | 623M | 725M | 839M | 900M | 1.04B | 1.13B |
| Cash & Short-term Investments | 48.5M | 48.4M | 62.8M | 93.7M | 182M | 173M | 177M | 176M | 150M | 123M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 142M | 108M | 83.6M | 132M | 119M | 130M | 99.0M | 119M | 204M | 199M |
| Capital Expenditure | 40.0M | 31.5M | 25.8M | 16.7M | 22.5M | 33.7M | 38.7M | 59.9M | 80.4M | 102M |
| Free Cash Flow | - | 69.6M | 49.8M | 109M | 89.9M | 82.7M | 45.4M | 58.7M | 124M | 96.9M |
| Ratios | ||||||||||
| ROE | 7.3% | -0.6% | 4.4% | 10.0% | 22.1% | 15.6% | 14.5% | 13.5% | 13.9% | 13.4% |
| ROA | 2.4% | -0.2% | 1.6% | 3.9% | 12.4% | 9.4% | 9.1% | 8.3% | 7.9% | 7.9% |
| Net Profit Margin | 4.0% | -0.3% | 2.3% | 5.5% | 14.7% | 10.6% | 10.0% | 9.7% | 10.4% | 10.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Virbac SA dividends
- Dividend yield
- 0.41%
- Forward dividend
- 1.45 EUR
- Payout ratio
- 8.1%
- Ex-dividend date
- Jul 2, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 12.1M | 1.45 | 8.1% |
| 2024 | EUR 11.1M | 1.32 | 7.6% |
| 2023 | EUR 11.2M | 1.33 | 9.2% |
| 2022 | EUR 10.6M | 1.25 | 8.7% |
| 2021 | EUR 6.34M | 0.75 | 5.6% |
| 2020 | EUR 6.34M | 0.75 | 4.6% |
| 2019 | EUR 6.34M | 0.75 | 12.3% |
| 2018 | EUR 6.34M | 0.75 | 31.6% |
| 2017 | - | - | - |
| 2016 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Virbac SA
- Insiders 50.82%
- Institutions 25.82%
- Public & others 23.36%
- Shares outstanding 8.38M
- Free float 4.13M
Virbac SA company profile
- Company name
- Virbac SA
- Ticker
- V16.F
- ISIN
- FR0000031577
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 6,442
- Fiscal year end
- December
- Address
- 13e rue LID - BP 27, Carros, France, 06511
- Phone
- 33 4 92 08 71 00
- Website
- corporate.virbac.com
About Virbac SA
Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, the United States, Brazil, and the Pacific. The company offers Vikaly, a cat food designed for the management of feline chronic kidney disease; Prevexto that contains imidacloprid and flumethrin, providing long-lasting parasite protection collar for dogs and cats at risk of fleas, ticks, lice, and sandflies; Zenidog/Zenifel offers a fogger, spray, and non-electric pheromone gel diffuser to soothe and reduce stress-related behaviors in dogs; Suigen Entero 3 is an inactivated vaccine aimed at preventing neonatal diarrhea in piglets caused by colibacillosis, clostridium, and rotavirus; Ursolyx soft chews formulated with ursolic acid that support muscle strength and mobility in dogs and cats; Zenifel a fogger and spray designed to reduce behaviors due to stress or undesirable behaviors in cats; Suigen PCV2 is a vaccine for porcine circovirus type 2; and Suigen Donoban is a multivalent vaccine used for the prevention of respiratory diseases in swine. It also provides a range of vaccines, antibiotics, parasiticides, and anti-inflammatory drugs, as well as dermatology, dental, specialty, diagnosis, immunology, nutrition, petfood, and pharmaceutical products. In addition, the company serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.
Virbac SA management
9- Mr. Paul MartingellChief Executive Officer · born 1981
- Mr. Habib RamdaniExecutive VP, Deputy CEO & CFO · born 1976
- Mr. Marc BistuerExecutive Vice President of Compliance · born 1962
- Mr. André MathieuExecutive Vice President of Operations
- Ms. Nathalie PolletExecutive Vice President of Global Marketing & Market Development
- Ms. Sophie FaviniExecutive Vice President of International Region
- Mr. Bertrand HavrileckExecutive Vice President of R&D
- Enguerrand DuboisExecutive Vice President of Europe Region
- Mr. Giovanni AbruzziniExecutive Vice President of North America Region